Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Demand For “Prediabetes” Supplements Exposes Marketing Risks

This article was originally published in The Tan Sheet

Executive Summary

Navigating legally among claims for prediabetes or blood sugar levels is tricky. Experts discuss what keeps a claim legal and what crosses the line, and spotlight other disease categories that can get firms in trouble if claims are not crafted properly.

You may also be interested in...



U.K. Allows Supplement Weight-Loss Claims Little Wiggle Room

As resolution season arrives, the advertising watchdog underscores the rules for weight-loss claims and testimonials. Boots Pharmaceuticals’ Carb Control made a common unsubstantiated diet aid claim – binding fats in the stomach so they are not absorbed by the body, helping users shed pounds, the agency says.

U.K. Allows Supplement Weight-Loss Claims Little Wiggle Room

As resolution season arrives, the advertising watchdog underscores the rules for weight-loss claims and testimonials. Boots Pharmaceuticals’ Carb Control made a common unsubstantiated diet aid claim – binding fats in the stomach so they are not absorbed by the body, helping users shed pounds, the agency says.

POM Decision Will Free FTC Resources For Other Enforcement

With the POM Wonderful litigation off its desk, FTC will have more resources to bring cases against other advertisers, attorney Mark Ullman warns. Likely target areas in 2013 and beyond include social media marketing and more subtle disease claims.

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel